Just days after announcing a US Food and Drug Adminstration filing for its CT-P42 biosimilar Eylea (aflibercept) candidate, Korea’s Celltrion has followed it up with a filing in both the US and Canada for its CT-P43 proposed rival to Stelara (ustekinumab).
The filing follows US filings for Stelara biosimilars from Amgen as well as the Teva-Alvotech alliance, with both ustekinumab rivals already the subject of settlement deals with Johnson & Johnson
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?